1. Phylogeny  
   Protein kinase C iota (PKCι), encoded by the PRKCI gene and also known as atypical protein kinase C‐lambda/iota or nPKC‐iota, is a member of the protein kinase C (PKC) family that falls under the atypical subgroup of the AGC kinase superfamily. Unlike conventional and novel PKC isoforms, which require calcium and diacylglycerol for activation, atypical PKCs have evolved distinct regulatory features that render them independent of such second messengers. Phylogenetic analyses place PKCι together with PKCζ in a clade of atypical PKCs that is evolutionarily conserved across eukaryotic species, indicating the critical and ancient role these kinases play in cellular signaling processes. Orthologs for PKCι have been identified in diverse mammalian species as well as in lower eukaryotes, reflecting its emergence early in eukaryotic evolution and its retention in key signaling pathways such as those controlling cell polarity, survival, and differentiation (newton2018proteinkinasec pages 14-15, robinson2025rarevariantsin pages 23-25, parker2014atypicalproteinkinase pages 2-4).
2. Reaction Catalyzed  
   PKCι catalyzes the transfer of the γ-phosphate group from ATP to the hydroxyl group of serine or threonine residues on target substrate proteins. In its canonical reaction, ATP and a protein substrate containing an appropriate serine/threonine residue are converted into ADP and a phosphorylated protein product, with the release of a proton (H⁺). This reaction is fundamental to cellular signaling, as the phosphorylation event modulates the activity, localization, and interactions of substrates involved in processes ranging from apoptosis resistance to cell polarity (parker2014atypicalproteinkinase pages 2-4, newton2001proteinkinasec pages 1-2).
3. Cofactor Requirements  
   The catalytic activity of PKCι is strictly dependent on the presence of divalent metal ions—predominantly Mg²⁺—which coordinate with ATP to facilitate the transfer of the phosphate group during the phosphorylation process. Despite the fact that many PKC isoforms are regulated by lipid cofactors such as diacylglycerol, atypical PKCs like PKCι do not require diacylglycerol or Ca²⁺ for activation. Instead, the enzyme relies on its binding to MgATP, with Mg²⁺ playing a critical role in stabilizing the ATP molecule in the active site, ensuring the efficient transfer of the phosphoryl moiety to substrates (kawano2021activatorsandinhibitors pages 1-2, webb2000proteinkinasec pages 1-2).
4. Substrate Specificity  
   PKCι exhibits a substrate specificity characteristic of serine/threonine kinases, targeting hydroxyl groups on serine or threonine residues within proteins. Although a single definitive consensus motif is not universally established in the literature provided, experimental studies have demonstrated that PKCι phosphorylates specific substrates such as the interleukin receptor-associated kinase (IRAK) at Thr66, thereby modulating downstream NF-κB activation (mamidipudi2004regulationofinterleukin pages 1-1). In addition, in oncogenic contexts such as non-small cell lung cancer (NSCLC), PKCι phosphorylates key regulatory proteins like ECT2, and it is implicated in the phosphorylation of pro-apoptotic factors such as BAD in glioblastoma cells, suggesting that substrates of PKCι may often feature clusters of basic residues that favor recognition by its catalytic domain (parker2014atypicalproteinkinase pages 7-8, ni2016pkciotapromotes pages 11-11). Moreover, the presence of its regulatory PB1 domain directs interactions with scaffolding proteins such as Par6, thereby further refining substrate selection by bringing PKCι into close proximity with specific targets involved in cell polarity and survival (newton2018proteinkinasec pages 28-30).
5. Structure  
   PKCι is organized into distinct regions that confer both its regulatory control and catalytic function. The N-terminal portion of the molecule contains a regulatory region that encompasses a Phox and Bem1 (PB1) domain. This PB1 domain is pivotal for mediating specific protein-protein interactions with key signaling partners such as Par6, p62, and MEK5, which serve to localize PKCι to defined intracellular compartments and modulate its activity. Adjacent to the PB1 domain is an atypical C1 domain. Unlike the tandem C1 domains of conventional and novel PKCs that bind diacylglycerol, the single C1 domain in PKCι is rendered non-responsive to diacylglycerol because of steric hindrance provided by surrounding basic residues (kawano2021activatorsandinhibitors pages 24-25, parker2014atypicalproteinkinase pages 2-4).

The C-terminal segment of PKCι consists of the catalytic kinase domain, which displays the characteristic bilobal structure common to protein kinases: an N-terminal lobe predominantly composed of β-sheets involved in ATP binding and a larger C-terminal lobe that is mostly α-helical and houses the substrate-binding site. Critical features within the catalytic domain include the activation loop, whose phosphorylation is essential for full enzymatic activity, and the hydrophobic motif that plays a role in stabilizing the active conformation of the enzyme. In addition, a pseudosubstrate segment within the regulatory region provides autoinhibition by occupying the substrate-binding pocket when the kinase is in its inactive state (newton2018proteinkinasec pages 3-4, steinberg2008structuralbasisof pages 33-33). The overall 3D structural organization of PKCι, as evidenced by crystallographic data and predictive models, reveals how its unique domain architecture underlies its insensitivity to conventional activators like Ca²⁺ and diacylglycerol while enabling precise regulation via phosphorylation and scaffolding interactions (parker2014atypicalproteinkinase pages 16-18, newton2018proteinkinasec pages 4-6).

1. Regulation  
   The activation and regulation of PKCι are controlled by several interdependent mechanisms. One of the central regulatory events is phosphorylation, particularly by phosphoinositide-dependent kinase-1 (PDK1), which phosphorylates the activation loop of PKCι—a modification that is essential for the enzyme’s catalytic competence. Following PDK1-mediated phosphorylation, PKCι undergoes additional autophosphorylation events at the turn and hydrophobic motifs, which help to stabilize the active conformation and protect the enzyme from phosphatase-mediated inactivation (newton2001proteinkinasec pages 1-2, newton2003regulationofthe pages 1-2, newton2018proteinkinasec pages 19-21).

In parallel with phosphorylation, PKCι is regulated by protein-protein interactions that largely occur through its PB1 domain. Binding to scaffolding proteins such as Par6, p62, and ECT2 not only assists in the spatial targeting of PKCι to specific intracellular locales such as membrane compartments and cytoskeletal structures but also promotes efficient substrate phosphorylation by maintaining the kinase in proximity to its targets. For example, in non-small cell lung cancer cells, the formation of a complex between PKCι, Par6, and ECT2 facilitates oncogenic signaling pathways by modulating cell polarity and migration (parker2014atypicalproteinkinase pages 20-23, robinson2025rarevariantsin pages 23-25).

Furthermore, the regulatory mechanisms of PKCι are distinct because the enzyme is calcium- and diacylglycerol-independent. This atypical mode of regulation ensures that its activation is primarily governed by phosphorylation status and scaffolding interactions rather than by fluctuations in intracellular calcium levels or lipid second messengers. The kinase’s activity is thus fine-tuned by the dynamic balance between phosphorylation events and the reversible association with interacting proteins, which together govern its role in cell survival and apoptosis prevention (newton2003regulationofthe pages 11-11, kawano2021activatorsandinhibitors pages 16-17).

1. Function  
   PKCι serves a multifaceted role in cellular physiology, with functions that extend from the regulation of apoptosis to the maintenance of cell polarity and the facilitation of oncogenic transformation. In hematological contexts, PKCι is indispensable for BCR-ABL oncogene-mediated drug resistance, as it protects leukemic cells from apoptosis induced by chemotherapeutic agents, thereby contributing to treatment resistance (information section, parker2014atypicalproteinkinase pages 5-7). In neuronal cultures, PKCι has been shown to interrupt the early stages of amyloid beta-induced cell death, thus acting as a protective factor against neurodegenerative insults (information section, newton2018proteinkinasec pages 14-15).

In glioblastoma cells, PKCι operates downstream of phosphatidylinositol 3-kinase (PI3K) and PDPK1 to promote cell survival. It achieves this, in part, by phosphorylating and inhibiting the pro-apoptotic factor BAD; such phosphorylation events contribute to the enhanced survival of tumor cells under stress conditions (information section, parker2014atypicalproteinkinase pages 8-9). Moreover, in non-small cell lung cancer cells, PKCι forms a protein complex with PARD6A and ECT2. Within this complex, PKCι-mediated phosphorylation of ECT2 modulates its oncogenic activity, which in turn drives transformed growth and invasive behavior—a critical step in tumor progression (parker2014atypicalproteinkinase pages 20-23, ni2016pkciotapromotes pages 11-11).

Beyond its role in cancer, PKCι is involved in the activation of NF-κB signaling cascades. By phosphorylating key intermediary proteins, PKCι enhances NF-κB activation, thereby promoting cell survival and inflammatory responses. This pro-survival function is particularly relevant in contexts where cells are exposed to cytotoxic or apoptotic stimuli (mamidipudi2004regulationofinterleukin pages 1-1, newton2001proteinkinasec pages 1-2). Collectively, the diverse functional roles of PKCι—in apoptosis inhibition, polarity regulation, and oncogenic signaling—underscore its importance as an integrator of cellular responses that are critical for both normal cellular homeostasis and disease pathogenesis (kawano2021activatorsandinhibitors pages 24-25, parker2014atypicalproteinkinase pages 9-11).

1. Other Comments  
   A number of chemical inhibitors have been developed that target PKCι, exploiting its unique structural domains. Gold-based compounds such as auranofin and sodium aurothiomalate inhibit PKCι by binding to cysteine residues located within the PB1 domain, thereby impeding its interactions with key adaptor proteins and disrupting oncogenic complexes (kawano2021activatorsandinhibitors pages 8-9). In addition, small molecule inhibitors like ICA-1 have been designed to selectively target the catalytic domain of PKCι, reducing its kinase activity and subsequently decreasing cell proliferation in various cancer models (kawano2021activatorsandinhibitors pages 9-10). Overexpression of PKCι is observed in several malignancies including non-small cell lung cancer, glioblastoma, and certain leukemias, where it is linked to apoptotic resistance and enhanced invasive potential (information section, parker2014atypicalproteinkinase pages 5-7, robinson2025rarevariantsin pages 25-25).

Moreover, rare genetic variants in the PRKCI gene have been implicated in developmental disorders such as Van der Woude syndrome and features of peridermopathy, highlighting the significance of PKCι beyond its oncogenic roles (robinson2025rarevariantsin pages 10-12). On the therapeutic front, the targeting of PKCι remains of considerable interest because of its central role in multiple key cellular signaling pathways. Ongoing efforts focus on not only refining the specificity and potency of the current inhibitors but also on uncovering novel regulatory mechanisms that could be leveraged in the development of innovative therapeutic strategies (kawano2021activatorsandinhibitors pages 16-17, singh2024proteinkinasec pages 16-17).

1. References
2. Kawano T, Inokuchi J, Eto M, Murata M, Kang J-H. Activators and inhibitors of protein kinase C (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. doi:10.3390/pharmaceutics13111748 (kawano2021activatorsandinhibitors pages 1-2, 8-9, 16-17, 22-24, 24-25, 9-10).
3. Kwiatkowski J, Liu B, Tee DHY, Chen G, Ahmad N, Wong YX, Poh ZY, Ang SH, Tan ES, Ong EHQ, Dinie N, Poulsen A, Pendharkar V, Sangthongpitag K, Lee MA, Sepramaniam S, Ho SY, Cherian J, Hill J, Keller TH, Hung AW. Fragment-based drug discovery of potent protein kinase C iota inhibitors. J Med Chem, 61:4386-4396, Apr 2018. doi:10.1021/acs.jmedchem.8b00060 (kwiatkowski2018fragmentbaseddrugdiscovery pages 9-10, 10-11).
4. Newton AC. Regulation of the abc kinases by phosphorylation: protein kinase c as a paradigm. Biochem J, 370:361-371, Mar 2003. doi:10.1042/bj20021626 (newton2003regulationofthe pages 1-2, 10-11).
5. Newton AC. Protein kinase c: perfectly balanced. Crit Rev Biochem Mol Biol, 53:208-230, Mar 2018. doi:10.1080/10409238.2018.1442408 (newton2018proteinkinasec pages 3-4, 14-15, 19-21, 22-23, 23-24, 27-28, 28-30, 3-4).
6. Parker PJ, Justilien V, Riou P, Linch M, Fields AP. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochem Pharmacol, 88:1-11, Mar 2014. doi:10.1016/j.bcp.2013.10.023 (parker2014atypicalproteinkinase pages 1-2, 2-4, 4-5, 5-7, 7-8, 8-9, 9-11, 11-12, 12-14, 15-16, 16-18, 18-19, 20-23).
7. Mamidipudi V, Lin C, Seibenhener ML, Wooten MW. Regulation of interleukin receptor-associated kinase (irak) phosphorylation and signaling by iota protein kinase c. J Biol Chem, 279:4161-4165, Feb 2004. doi:10.1074/jbc.c300431200 (mamidipudi2004regulationofinterleukin pages 1-1, 4-5).
8. Uhalte EC, Kirchner M, Hellwig N, Allen JJ, Donat S, Shokat KM, Selbach M, Abdelilah-Seyfried S. In vivo conditions to identify prkci phosphorylation targets using the analog-sensitive kinase method in zebrafish. PLoS One, 7:e40000, Jun 2012. doi:10.1371/journal.pone.0040000 (uhalte2012invivoconditions pages 1-2).
9. Ni S, Chen L, Li M, Zhao W, Shan X, Wu M, Cheng J, Liang L, Wang Y, Jiang W, Zhang J, Ni R. Pkc iota promotes cellular proliferation by accelerated g1/s transition via interaction with cdk7 in esophageal squamous cell carcinoma. Tumor Biol, 37:13799-13809, Aug 2016. doi:10.1007/s13277-016-5193-9 (ni2016pkciotapromotes pages 11-11).
10. Robinson KR, Singh SK, Walkup RB, Fawwal DV, Adeyemo WL, Beaty TH, Butali A, Buxó CJ, Chung WK, Cutler DJ, Epstein MP, Fashina A, Gasser B, Gowans LJ, Hecht JT, Moreno Uribe L, Scott DA, Shaw GM, Thomas MA, Weinberg SM, Brand H, Marazita ML, Lipinski RJ, Murray JC, Cornell RA, Leslie-Clarkson EJ. Rare variants in prkci cause van der woude syndrome and other features of peridermopathy. MedRxiv, Jan 2025. doi:10.1101/2025.01.17.25320742 (robinson2025rarevariantsin pages 10-12, 23-25, 25-25).
11. Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V. Targeting atypical protein kinase c iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer, Oct 2016. doi:10.1002/ijc.30234 (phillips2016targetingatypicalprotein pages 18-22).
12. Singh N, Nandy SK, Jyoti A, Saxena J, Sharma A, Siddiqui AJ, Sharma L. Protein kinase c (pkc) in neurological health: implications for alzheimer’s disease and chronic alcohol consumption. Brain Sci, 14:554, May 2024. doi:10.3390/brainsci14060554 (singh2024proteinkinasec pages 16-17).
13. Steinberg SF. Structural basis of protein kinase c isoform function. Physiol Rev, 88:1341-1378, Oct 2008. doi:10.1152/physrev.00034.2007 (steinberg2008structuralbasisof pages 1-2, 3-5, 33-33, 37-39).
14. Webb BLJ, Hirst SJ, Giembycz MA. Protein kinase c isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. Br J Pharmacol, 130:1433-1452, Aug 2000. doi:10.1038/sj.bjp.0703452 (webb2000proteinkinasec pages 1-2).

References

1. (kawano2021activatorsandinhibitors pages 24-25): Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, and Jeong-Hun Kang. Activators and inhibitors of protein kinase c (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. URL: https://doi.org/10.3390/pharmaceutics13111748, doi:10.3390/pharmaceutics13111748. This article has 99 citations and is from a peer-reviewed journal.
2. (kwiatkowski2018fragmentbaseddrugdiscovery pages 9-10): Jacek Kwiatkowski, Boping Liu, Doris Hui Ying Tee, Guoying Chen, Nur Huda Binte Ahmad, Yun Xuan Wong, Zhi Ying Poh, Shi Hua Ang, Eldwin Sum Wai Tan, Esther HQ Ong, Nurul Dinie, Anders Poulsen, Vishal Pendharkar, Kanda Sangthongpitag, May Ann Lee, Sugunavathi Sepramaniam, Soo Yei Ho, Joseph Cherian, Jeffrey Hill, Thomas H. Keller, and Alvin W. Hung. Fragment-based drug discovery of potent protein kinase c iota inhibitors. Journal of Medicinal Chemistry, 61:4386-4396, Apr 2018. URL: https://doi.org/10.1021/acs.jmedchem.8b00060, doi:10.1021/acs.jmedchem.8b00060. This article has 23 citations and is from a highest quality peer-reviewed journal.
3. (newton2003regulationofthe pages 11-11): Alexandra C. NEWTON. Regulation of the abc kinases by phosphorylation: protein kinase c as a paradigm. Biochemical Journal, 370:361-371, Mar 2003. URL: https://doi.org/10.1042/bj20021626, doi:10.1042/bj20021626. This article has 1070 citations and is from a domain leading peer-reviewed journal.
4. (newton2018proteinkinasec pages 14-15): Alexandra C. Newton. Protein kinase c: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology, 53:208-230, Mar 2018. URL: https://doi.org/10.1080/10409238.2018.1442408, doi:10.1080/10409238.2018.1442408. This article has 318 citations and is from a peer-reviewed journal.
5. (parker2014atypicalproteinkinase pages 16-18): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
6. (parker2014atypicalproteinkinase pages 2-4): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
7. (parker2014atypicalproteinkinase pages 7-8): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
8. (parker2014atypicalproteinkinase pages 9-11): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
9. (robinson2025rarevariantsin pages 23-25): Kelsey R. Robinson, Sunil K. Singh, Rachel B Walkup, Dorelle V. Fawwal, Wasiu Lanre Adeyemo, Terri H. Beaty, Azeez Butali, Carmen J. Buxó, Wendy K. Chung, David J. Cutler, Michael P. Epstein, Azeez Fashina, Brooklynn Gasser, Lord J.J. Gowans, Jacqueline T. Hecht, Lina Moreno Uribe, Daryl A. Scott, Gary M. Shaw, Mary Ann Thomas, Seth M. Weinberg, Harrison Brand, Mary L. Marazita, Robert J Lipinski, Jeffrey C. Murray, Robert A. Cornell, and Elizabeth J. Leslie-Clarkson. Rare variants in prkci cause van der woude syndrome and other features of peridermopathy. MedRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.17.25320742, doi:10.1101/2025.01.17.25320742. This article has 0 citations.
10. (uhalte2012invivoconditions pages 1-2): Elena Cibrián Uhalte, Marieluise Kirchner, Nicole Hellwig, Jasmina J. Allen, Stefan Donat, Kevan M. Shokat, Matthias Selbach, and Salim Abdelilah-Seyfried. In vivo conditions to identify prkci phosphorylation targets using the analog-sensitive kinase method in zebrafish. PLoS ONE, 7:e40000, Jun 2012. URL: https://doi.org/10.1371/journal.pone.0040000, doi:10.1371/journal.pone.0040000. This article has 16 citations and is from a peer-reviewed journal.
11. (kawano2021activatorsandinhibitors pages 1-2): Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, and Jeong-Hun Kang. Activators and inhibitors of protein kinase c (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. URL: https://doi.org/10.3390/pharmaceutics13111748, doi:10.3390/pharmaceutics13111748. This article has 99 citations and is from a peer-reviewed journal.
12. (kawano2021activatorsandinhibitors pages 16-17): Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, and Jeong-Hun Kang. Activators and inhibitors of protein kinase c (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. URL: https://doi.org/10.3390/pharmaceutics13111748, doi:10.3390/pharmaceutics13111748. This article has 99 citations and is from a peer-reviewed journal.
13. (kawano2021activatorsandinhibitors pages 8-9): Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, and Jeong-Hun Kang. Activators and inhibitors of protein kinase c (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. URL: https://doi.org/10.3390/pharmaceutics13111748, doi:10.3390/pharmaceutics13111748. This article has 99 citations and is from a peer-reviewed journal.
14. (mamidipudi2004regulationofinterleukin pages 1-1): Vidya Mamidipudi, Chunru Lin, M. Lamar Seibenhener, and Marie W. Wooten. Regulation of interleukin receptor-associated kinase (irak) phosphorylation and signaling by iota protein kinase c. Journal of Biological Chemistry, 279:4161-4165, Feb 2004. URL: https://doi.org/10.1074/jbc.c300431200, doi:10.1074/jbc.c300431200. This article has 43 citations and is from a domain leading peer-reviewed journal.
15. (newton2001proteinkinasec pages 1-2): Alexandra C. Newton. Protein kinase c: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chemical Reviews, 101:2353-2364, Jun 2001. URL: https://doi.org/10.1021/cr0002801, doi:10.1021/cr0002801. This article has 1267 citations and is from a highest quality peer-reviewed journal.
16. (newton2018proteinkinasec pages 28-30): Alexandra C. Newton. Protein kinase c: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology, 53:208-230, Mar 2018. URL: https://doi.org/10.1080/10409238.2018.1442408, doi:10.1080/10409238.2018.1442408. This article has 318 citations and is from a peer-reviewed journal.
17. (newton2018proteinkinasec pages 4-6): Alexandra C. Newton. Protein kinase c: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology, 53:208-230, Mar 2018. URL: https://doi.org/10.1080/10409238.2018.1442408, doi:10.1080/10409238.2018.1442408. This article has 318 citations and is from a peer-reviewed journal.
18. (ni2016pkciotapromotes pages 11-11): Sujie Ni, Lingling Chen, Mei Li, Weijuan Zhao, Xiaohang Shan, Miaomiao Wu, Jialin Cheng, Li Liang, Yayun Wang, Wenyan Jiang, Jianguo Zhang, and Runzhou Ni. Pkc iota promotes cellular proliferation by accelerated g1/s transition via interaction with cdk7 in esophageal squamous cell carcinoma. Tumor Biology, 37:13799-13809, Aug 2016. URL: https://doi.org/10.1007/s13277-016-5193-9, doi:10.1007/s13277-016-5193-9. This article has 16 citations and is from a peer-reviewed journal.
19. (parker2014atypicalproteinkinase pages 1-2): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
20. (parker2014atypicalproteinkinase pages 20-23): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
21. (parker2014atypicalproteinkinase pages 5-7): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
22. (parker2014atypicalproteinkinase pages 8-9): Peter J. Parker, Verline Justilien, Philippe Riou, Mark Linch, and Alan P. Fields. Atypical protein kinase cι as a human oncogene and therapeutic target. Biochemical Pharmacology, 88:1-11, Mar 2014. URL: https://doi.org/10.1016/j.bcp.2013.10.023, doi:10.1016/j.bcp.2013.10.023. This article has 115 citations and is from a domain leading peer-reviewed journal.
23. (phillips2016targetingatypicalprotein pages 18-22): Emma Phillips, Verena Lang, Jonathan Bohlen, Frederic Bethke, Laura Puccio, Diana Tichy, Christel Herold‐Mende, Thomas Hielscher, Peter Lichter, and Violaine Goidts. Targeting atypical protein kinase c iota reduces viability in glioblastoma stem‐like cells via a notch signaling mechanism. International Journal of Cancer, Oct 2016. URL: https://doi.org/10.1002/ijc.30234, doi:10.1002/ijc.30234. This article has 38 citations and is from a domain leading peer-reviewed journal.
24. (robinson2025rarevariantsin pages 25-25): Kelsey R. Robinson, Sunil K. Singh, Rachel B Walkup, Dorelle V. Fawwal, Wasiu Lanre Adeyemo, Terri H. Beaty, Azeez Butali, Carmen J. Buxó, Wendy K. Chung, David J. Cutler, Michael P. Epstein, Azeez Fashina, Brooklynn Gasser, Lord J.J. Gowans, Jacqueline T. Hecht, Lina Moreno Uribe, Daryl A. Scott, Gary M. Shaw, Mary Ann Thomas, Seth M. Weinberg, Harrison Brand, Mary L. Marazita, Robert J Lipinski, Jeffrey C. Murray, Robert A. Cornell, and Elizabeth J. Leslie-Clarkson. Rare variants in prkci cause van der woude syndrome and other features of peridermopathy. MedRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.17.25320742, doi:10.1101/2025.01.17.25320742. This article has 0 citations.
25. (webb2000proteinkinasec pages 1-2): Benjamin L J Webb, Stuart J Hirst, and Mark A Giembycz. Protein kinase c isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis. British Journal of Pharmacology, 130:1433-1452, Aug 2000. URL: https://doi.org/10.1038/sj.bjp.0703452, doi:10.1038/sj.bjp.0703452. This article has 231 citations and is from a highest quality peer-reviewed journal.
26. (kawano2021activatorsandinhibitors pages 9-10): Takahito Kawano, Junichi Inokuchi, Masatoshi Eto, Masaharu Murata, and Jeong-Hun Kang. Activators and inhibitors of protein kinase c (pkc): their applications in clinical trials. Pharmaceutics, 13:1748, Oct 2021. URL: https://doi.org/10.3390/pharmaceutics13111748, doi:10.3390/pharmaceutics13111748. This article has 99 citations and is from a peer-reviewed journal.
27. (newton2003regulationofthe pages 1-2): Alexandra C. NEWTON. Regulation of the abc kinases by phosphorylation: protein kinase c as a paradigm. Biochemical Journal, 370:361-371, Mar 2003. URL: https://doi.org/10.1042/bj20021626, doi:10.1042/bj20021626. This article has 1070 citations and is from a domain leading peer-reviewed journal.
28. (newton2018proteinkinasec pages 19-21): Alexandra C. Newton. Protein kinase c: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology, 53:208-230, Mar 2018. URL: https://doi.org/10.1080/10409238.2018.1442408, doi:10.1080/10409238.2018.1442408. This article has 318 citations and is from a peer-reviewed journal.
29. (newton2018proteinkinasec pages 3-4): Alexandra C. Newton. Protein kinase c: perfectly balanced. Critical Reviews in Biochemistry and Molecular Biology, 53:208-230, Mar 2018. URL: https://doi.org/10.1080/10409238.2018.1442408, doi:10.1080/10409238.2018.1442408. This article has 318 citations and is from a peer-reviewed journal.
30. (robinson2025rarevariantsin pages 10-12): Kelsey R. Robinson, Sunil K. Singh, Rachel B Walkup, Dorelle V. Fawwal, Wasiu Lanre Adeyemo, Terri H. Beaty, Azeez Butali, Carmen J. Buxó, Wendy K. Chung, David J. Cutler, Michael P. Epstein, Azeez Fashina, Brooklynn Gasser, Lord J.J. Gowans, Jacqueline T. Hecht, Lina Moreno Uribe, Daryl A. Scott, Gary M. Shaw, Mary Ann Thomas, Seth M. Weinberg, Harrison Brand, Mary L. Marazita, Robert J Lipinski, Jeffrey C. Murray, Robert A. Cornell, and Elizabeth J. Leslie-Clarkson. Rare variants in prkci cause van der woude syndrome and other features of peridermopathy. MedRxiv, Jan 2025. URL: https://doi.org/10.1101/2025.01.17.25320742, doi:10.1101/2025.01.17.25320742. This article has 0 citations.
31. (singh2024proteinkinasec pages 16-17): Nishtha Singh, Shouvik Kumar Nandy, Anupam Jyoti, Juhi Saxena, Aditi Sharma, Arif Jamal Siddiqui, and Lalit Sharma. Protein kinase c (pkc) in neurological health: implications for alzheimer’s disease and chronic alcohol consumption. Brain Sciences, 14:554, May 2024. URL: https://doi.org/10.3390/brainsci14060554, doi:10.3390/brainsci14060554. This article has 11 citations and is from a peer-reviewed journal.
32. (steinberg2008structuralbasisof pages 1-2): Susan F. Steinberg. Structural basis of protein kinase c isoform function. Physiological Reviews, 88:1341-1378, Oct 2008. URL: https://doi.org/10.1152/physrev.00034.2007, doi:10.1152/physrev.00034.2007. This article has 1161 citations and is from a highest quality peer-reviewed journal.
33. (steinberg2008structuralbasisof pages 33-33): Susan F. Steinberg. Structural basis of protein kinase c isoform function. Physiological Reviews, 88:1341-1378, Oct 2008. URL: https://doi.org/10.1152/physrev.00034.2007, doi:10.1152/physrev.00034.2007. This article has 1161 citations and is from a highest quality peer-reviewed journal.